Amicus Therapeutics (FOLD): Revenue Loss from migalastat Drives PT Cut - Baird

November 29, 2016 7:00 AM EST
Get Alerts FOLD Hot Sheet
Price: $6.09 +0.66%

Rating Summary:
    8 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade FOLD Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Baird analyst, Michael Ulz, reiterated his Neutral rating on shares of Amicus Therapeutics (NASDAQ: FOLD) and cut his price target to $7 from $9 after the company provided a disappointing update on the regulatory path forward for migalastat in the US. The company now requires an additional gastrointestinal (GI) study, delaying timelines.

Expectations embed existing data supporting an accelerated approval (Galafold approved in Europe). While the GI data is not expected until 2019 and could lead to full approval but in the interim he is removing US migalastat revenues from the model.

No change to the Neutral rating, but expect shares to be under pressure.

For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.

Shares of Amicus Therapeutics closed at $8.32 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Robert W Baird

Add Your Comment